Citation Impact
Citing Papers
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
2009 Standout
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Treatment of kidney cancer
2009 StandoutNobel
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage
2008 StandoutNobel
The role of cytoreductive nephrectomy in the era of molecular targeted therapy
2009
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
2007 StandoutNobel
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Renal cell carcinoma
2009
Renal Cell Carcinoma Guideline
2007
De novo protein design. I. in search of stability and specificity
1999 StandoutNobel
Cancer drug resistance: an evolving paradigm
2013 Standout
Reversal of Multidrug Resistance by 7-O-Benzoylpyripyropene A in Multidrug-Resistant Tumor Cells.
2000 StandoutNobel
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
2014
Renal-Cell Carcinoma
1996 Standout
Interferon–Alpha Suppresses the Antiapoptotic Effect of NF–kB and Sensitizes Renal Cell Carcinoma Cells in vitro to Chemotherapeutic Drugs
2001
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
1996 StandoutNature
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
2000 Standout
Kt-5720 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human MDR1 cDNA and in human multidrug-resistant carcinoma cells
1995
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA
2014
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells
2010
P-Glycoproteins and Multidrug Resistance
1996
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference
2009 StandoutNobel
GENETIC ANALYSIS OF THE MULTIDRUG TRANSPORTER
1995
EAU Guidelines on Renal Cell Carcinoma: The 2010 Update
2010
Structure-activity relationship of verapamil analogs and reversal of multidrug resistance
1995
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
2009
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
2013
Echinocandin antifungal drugs
2003 Standout
Bladder cancer
2016 Standout
Clinical trials of p-glycoprotein reversal in solid tumours
1996
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer
2003
Mechanisms of acquired resistance to cisplatin
1994
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2013 Standout
Inverse‐electron‐demand Diels‐Alder reaction as a highly efficient chemoselective ligation procedure: Synthesis and function of a BioShuttle for temozolomide transport into prostate cancer cells
2009
Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance
2007
Cu-free click cycloaddition reactions in chemical biology
2010 StandoutNobel
Novel treatment strategies in clear-cell metastatic renal cell carcinoma
2005
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
1995
Fluorogenic probes for live-cell imaging of the cytoskeleton
2014 StandoutNobel
Current strategies in the management of hormone refractory prostate cancer
2003
Renal cell carcinoma: Current status and emerging therapies
2007
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
1993 Standout
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
2008 Standout
Local treatments for metastases of renal cell carcinoma: a systematic review
2014
Pharmacologic circumvention of multidrug resistance
1993
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
2008
Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture
1994
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Regulatory networks defining EMT during cancer initiation and progression
2013 Standout
Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)
2013
Function and Regulation of the Human Multidrug Resistance Gene
1992
Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial
2008
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
1994
Tumour stem cells and drug resistance
2005 Standout
Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma
2006
Anti-cancer-prostaglandin-induced cell-cycle arrest and its modulation by an inhibitor of the ATP-dependent glutathione S-conjugate export pump (GS-X pump)
1998 StandoutNobel
Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy
1999
Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
1995
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
1999 Standout
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
2000 Standout
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
2000
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
2006
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
Proliferation of multipotent hematopoietic cells controlled by a truncated erythropoietin receptor transgene.
1996 StandoutNobel
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Immunotherapy for renal cell cancer in the era of targeted therapy
2008
Nanoparticles in Photodynamic Therapy
2015 Standout
Phosphatidylcholine and Phosphatidylethanolamine Behave as Substrates of the Human MDR1 P-Glycoprotein
1997
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
Hematopoietic stem cells with controllable tEpoR transgenes have a competitive advantage in bone marrow transplantation
2000 StandoutNobel
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Choroid plexus epithelial expression of MDR 1 P glycoprotein and multidrug resistance-associated protein contribute to the blood–cerebrospinal-fluid drug-permeability barrier
1999
A Bioorthogonal Quadricyclane Ligation
2011 StandoutNobel
Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer
2014
Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells.
1993
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans
2000
Metal–Organic Frameworks in Biomedicine
2011 Standout
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
1992
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
1999 Standout
Immunotoxins for targeted cancer therapy
1998
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
1999
Targeted therapy for advanced renal cell carcinoma
2008
Selection of Drug-Resistant Bone Marrow Cells in Vivo After Retroviral Transfer of Human MDR 1
1992 Science
Bcl-2 and the regulation of programmed cell death
1994 Standout
Works of G. Mickisch being referenced
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma
1995
Rational Selection of a Control Arm for Randomised Trials in Metastatic Renal Cell Carcinoma
2003
A phase II study of temozolomide in hormone-refractory prostate cancer
2000
Multidrug resistant transgenic mice as a novel pharmacologic tool
1991
Immunotherapy of Renal Cell Carcinoma
1999
Chemoresistance of renal cell carcinoma: 1986?1994
1994
Increased Effectiveness of Liposome-Encapsulated Doxorubicin in Multidrug-Resistant-Transgenic Mice Compared With Free Doxorubicin
1992
Multimodality treatment of metastatic renal cell carcinoma
2002
Guidelines on Renal Cell Cancer
2001
Establishment and characterization of cisplatin-Resistant sublines of the human squamous carcinoma cell line HLac 79
1990
Combination of surgery and immunotherapy in metastatic renal cell carcinoma
2005
Principles of nephrectomy for malignant disease
2002
Muscle-Invasive Urothelial Carcinoma of the Bladder
2007
Circumvention of Multidrug Resistance Mediated by P-170 Glycoprotein Using Calcium Antagonists in Primary Human Renal Cell Carcinoma
1991
Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice.
1992
EXPRESSION OF MULTIDRUG RESISTANCE RELATED PROTEINS AND PROLIFERATIVE ACTIVITY IS INCREASED IN ADVANCED CLINICAL PROSTATE CANCER
2001
A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy
2002
Randomized Phase II/III Trial of Interferon Alfa-2a With and Without 13-cis-Retinoic Acid in Patients With Progressive Metastatic Renal Cell Carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951)
2005
Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis
2004
Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity.
1991
New Potent Verapamil Derivatives that Reverse Multidrug Resistance in Human Renal Carcinoma Cells and in Transgenic Mice Expressing the HumanMDR1 Gene
1991
Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas.
1990
Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance.
1991
Mechanisms and Modulation of Multidrug Resistance in Primary Human Renal Cell Carcinoma
1990
Establishment and Characterization of Cisplatin-Resistant Sublines of the Human Squamous Carcinoma Cell Line HLac 79
1990
Pseudomonas Exotoxin Conjugated to Monoclonal Antibody MRK16 Specifically Kills Multidrug Resistant Cells in Cultured Renal Carcinomas and In Mdr-Transgenic Mice
1993